Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T cells. There is no word yet on the wholesale acquisition cost.
The FDA has approved Aucatzyl (obecabtagene autoleucel or obe-cel) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Acute lymphoblastic leukemia is a fast-growing cancer in which B-cell lymphoblasts are found in the bone marrow and blood. It accounts for less than half of 1% of all cancers in the United States. The American Cancer Society estimates that in 2024 there will be about 6,550 new cases of ALL and about 1,330 deaths.
Approximately 8,400 new cases of adult ALL are diagnosed every year in the United States and European Union, with around 3,000 patients in the relapsed refractory setting. Survival rates remain very poor in adult patients with r/r ALL, with median overall survival of eight months.
“Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients with this disease once they relapse, where historically they suffer from poor outcomes,” Elias Jabbour, M.D., U.S. lead investigator and professor of Leukemia, ALL Section Chief, at The University of Texas MD Anderson Cancer Center, Houston, said in a news release.
Developed by Autolus Therapeutics, Aucatzyl is a B-lymphocyte antigen CD19 chimeric antigen receptor (CAR) T cell therapy. It was designed to minimize excessive activation of the programmed T cells. There is no word yet on the wholesale acquisition cost or when Aucatzyl will be available.
The approval was based on data from the FELIX clinical trial. In the 65 patients evaluated for efficacy, 63% achieved overall complete remission (OCR), which includes 51% of patients with complete remission at any time and 12% patients with complete remission with incomplete hematologic recover at any time. The major efficacy outcome was complete remission within 3 months, which was achieved in 42% patients, and the median duration of remission was 14.1 months.
Aucatzyl showed low levels of cytokine release syndrome (CRS), with 3% grade 3 events, and no grade 4 or 5 events. The label includes a boxed warning about the risk of cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies.
According to company officials, Aucatzyl is the first CAR T-cell therapy approved by the FDA with no requirement for a Risk Evaluation and Mitigation Strategy (REMS) program.
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More